TTrialPathMatch Me to Trials
← Back to trials
RecruitingAutoimmune Haemolytic Anaemia

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Eligible age

18+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA. Following a 4-week screening period, eligible participants will be randomized in a 2:1 ratio to receive rilzabrutinib or placebo in primary analysis period (PAP) for a duration of up to 24 weeks. All participants who completed PAP will then continue in open-label period (OLP) to receive rilzabrutinib for a duration of 28 weeks. Upon the completion of OLP, only participants who demonstrate Hb increase during the last 8 weeks of OLP per specified criteria in the protocol will be eligible to continue in long-term extension (LTE) of the study. The duration of the LTE period will be from the first-participant-in (FPI)-LTE until the last participant completes 52 weeks in LTE. The safety follow-up period of this study following treatment completion or discontinuation will be 2 weeks.

Sponsor: Sanofi

You may qualify if…

  • ✓ Male and female participants with a documented (confirmed) diagnosis of primary wAIHA for at least 6 months.
  • ✓ Participants who have previously failed to maintain a sustained response after treatment with CS (CS-resistance \[defined as failure to obtain hemoglobin response within 3 weeks on at least 1 mg/kg or 60 mg prednisone or equivalent per day\], CS-dependent wAIHA \[defined as need to continue on prednisone or equivalent at a dose of \>10 mg/day to maintain a response\]), or are intolerant or ineligible to CS (defined as with contraindications, pre-existing medical conditions or CS-related complications that may render CS intolerant or ineligible per the best clinical judgement of the investigators).
  • ✓ Participants with Eastern Cooperative Oncology Group (ECOG) performance status Grade 2 or lower.
  • ✓ Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

You may not qualify if…

  • ✕ Participants with clinically significant medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his or her participation in the study as determined by the Investigator.
  • ✕ Participants with medical history of lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for the past 3 years.
  • ✕ Participants with symptomatic herpes zoster within 3 months prior to screening.
  • ✕ Participants with mixed wAIHA, or secondary wAIHA from any cause including drugs, Evans Syndrome, lymphoproliferative disorders (low count monoclonal B-cell lymphocytosis is allowed), infectious or autoimmune disease, or active hematologic malignancies. Participants with positive antinuclear antibodies but without a definitive diagnosis of an autoimmune disease are allowed.
  • ✕ Participants with history of myelodysplastic syndrome.
  • ✕ Participants with uncontrolled or active HBV infection or Active HCV infection.
  • ✕ HIV infection.
  • ✕ Participants with history of solid organ transplant.

Where it's recruiting

Arizona

Phoenix · Tucson

California

Duarte · Los Alamitos · Los Angeles · Stanford …

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

Hialeah · Miami · Tamarac

Louisiana

New Orleans

Michigan

Ann Arbor · Detroit

Minnesota

Rochester

New York

The Bronx

Ohio

Cleveland · Columbus

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT07086976 · last updated 2026-11-17

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of O · TrialPath